Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
43
TXMD Quote, Financials, Valuation and Earnings
Last price:
$1.70
Seasonality move
:
8.42%
Day range:
$1.61 - $1.74
52-week range:
$0.70 - $2.44
Dividend yield:
0%
P/E ratio:
65.38x
P/S ratio:
7.03x
P/B ratio:
0.72x
Volume:
52K
Avg. volume:
129.6K
1-year change:
55.96%
Market cap:
$19.7M
Revenue:
$1.8M
EPS (TTM):
$0.03
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, TherapeuticsMD, Inc. has 194.12% upside to fair value with a price target of -- per share.
TXMD vs. S&P 500
-
Over the past 5 trading days, TherapeuticsMD, Inc. has underperformed the S&P 500 by -2.96% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
TherapeuticsMD, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
TherapeuticsMD, Inc. has grown year-over-year revenues for 5 quarters straight. In the most recent quarter TherapeuticsMD, Inc. reported revenues of $784K.
Earnings Growth
-
TherapeuticsMD, Inc. has grown year-over-year earnings for 8 quarters straight. In the most recent quarter TherapeuticsMD, Inc. reported earnings per share of $0.01.
Enterprise value:
19M
EV / Invested capital:
0.56x
Price / LTM sales:
7.03x
EV / EBIT:
--
EV / Revenue:
6.81x
PEG ratio (5yr expected):
--
EV / Free cash flow:
9.21x
Price / Operating cash flow:
9.50x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$2.4M
Return On Assets:
0.19%
Net Income Margin (TTM):
2.61%
Return On Equity:
0.27%
Return On Invested Capital:
0.21%
Operating Margin:
-105.87%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.2M | $1.6M | $2.8M | $547K | $784K | |
| Gross Profit | $242K | $550K | $2.4M | $451K | $688K | |
| Operating Income | -$21.4M | -$4.8M | -$2.6M | -$859K | -$830K | |
| EBITDA | -$20.9M | -$3.7M | -$2.2M | -$763K | -$734K | |
| Diluted EPS | -$4.05 | -$0.29 | $0.03 | -$0.05 | $0.01 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $160M | $85.1M | $15.1M | $9.8M | $12.2M | |
| Total Assets | $209.6M | $133.9M | $50.5M | $39.6M | $38.7M | |
| Current Liabilities | $86.3M | $174.1M | $14.5M | $6M | $4.9M | |
| Total Liabilities | $267M | $182.2M | $22.4M | $12.5M | $11.2M | |
| Total Equity | -$57.4M | -$48.3M | $28.1M | $27.1M | $27.4M | |
| Total Debt | $195M | $101.2M | $6.7M | $5.8M | $5.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$7.1M | $2.1M | -$185K | $1M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | $2M | -- | -- | -- | |
| Free Cash Flow | -- | -$7.1M | $2.1M | -$185K | $1M | |
TXMD
Sector
Market Cap
$19.7M
$28.3M
Price % of 52-Week High
69.67%
51.3%
Dividend Yield
0%
0%
Shareholder Yield
1.78%
-1.42%
1-Year Price Total Return
55.96%
-17.78%
Beta (5-Year)
0.414
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.73
200-day SMA
Buy
Level
$1.21
Bollinger Bands (100)
Buy
Level
1.02 - 1.54
Chaikin Money Flow
Buy
Level
4.1K
20-day SMA
Buy
Level
$1.68
Relative Strength Index (RSI14)
Buy
Level
53.66
ADX Line
Sell
Level
6.89
Williams %R
Neutral
Level
-53.4483
50-day SMA
Buy
Level
$1.47
MACD (12, 26)
Buy
Level
0.32
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
102.2K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-33.9094)
Buy
CA Score
(Annual)
Level (0.0392)
Buy
Beneish M-Score
(Annual)
Level (-3.6064)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.2532)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.
Stock Forecast FAQ
In the current month, TXMD has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TXMD average analyst price target in the past 3 months is --.
-
Where Will TherapeuticsMD, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that TherapeuticsMD, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About TherapeuticsMD, Inc.?
Analysts are divided on their view about TherapeuticsMD, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that TherapeuticsMD, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is TherapeuticsMD, Inc.'s Price Target?
The price target for TherapeuticsMD, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TXMD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for TherapeuticsMD, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of TXMD?
You can purchase shares of TherapeuticsMD, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase TherapeuticsMD, Inc. shares.
-
What Is The TherapeuticsMD, Inc. Share Price Today?
TherapeuticsMD, Inc. was last trading at $1.70 per share. This represents the most recent stock quote for TherapeuticsMD, Inc.. Yesterday, TherapeuticsMD, Inc. closed at $1.70 per share.
-
How To Buy TherapeuticsMD, Inc. Stock Online?
In order to purchase TherapeuticsMD, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get TXMD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TXMD
Sector
P/E ratio
65.38x
23.99x
PEG ratio
--
-0.01x
P/B ratio
0.72x
1.80x
Price / LTM sales
7.03x
1.59x
Growth Metrics
TXMD
Sector
Revenue growth
43.33%
4.62%
Earnings growth
124.81%
10.71%
Revenue (5-year growth)
-48.72%
6.5%
Earnings forecast
--
-$0.20
Profitability
TXMD
Sector
Profitability FY 2024
$1.3M
$3.6M
Return on invested capital
0.21%
-31.84%
Return on assets
0.19%
-27.96%
Return on equity
0.27%
-37.47%
Earnings Date
Last Earnings Date
May
13
Next Earnings Date
Dec
20
Estimated Next Earnings Date
Mar
21
Balance Sheet
TXMD
Sector
Total cash
$7.1M
$26.4M
Short term investments
--
$25.7M
Total assets
$38.8M
$78M
Long term debt
$5.4M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
